logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Daphne Wu

university of toronto
H指数:13
被引数:1,075

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial

Niraparib和Abiraterone Acetate联合Prednisone治疗转移性去势抵抗性前列腺癌：MAGNITUDE III期试验最终总生存分析

European Urology Oncology
IF9.3
2025-05-050
OAAI
Kim N. Chi; Elena Castro; Gert Attard; Matthew R. Smith; Shahneen Sandhu; Eleni Efstathiou; Guilhem Roubaud; Eric J. Small; Andrea Pereira de Santana Gomes; Dana E. Rathkopf; Marniza Saad; Howard Gurney; Wonho Jung; Won Kim; Shiva Dibaj; Daphne Wu; Jenny Zhang; Angela Lopez-Gitlitz; Peter Francis; David Olmos
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
FUTURE ONCOLOGY
IF2.6
2025-03-010
OAAI
Chi, Kim N.; Rathkopf, Dana; Smith, Matthew R.; Efstathiou, Eleni; Attard, Gerhardt; Olmos, David; Lee, Ji Youl; Small, Eric J.; Gomes, Andrea J. Pereira de Santana; Roubaud, Guilhem; Saad, Marniza; Zurawski, Bogdan; Sakalo, Valerii; Mason, Gary E.; Francis, Peter; Wang, George; Wu, Daphne; Diorio, Brooke; Lopez-Gitlitz, Angela; Sandhu, Shahneen
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial

携带BRCA1/2基因变异的转移性去势抵抗性前列腺癌患者报告结局：随机III期MAGNITUDE试验的最终分析

European Urology
IF25.2
2024-09-230
OAAI
Dana E. Rathkopf; Guilhem Roubaud; Kim N. Chi; Eleni Efstathiou; Gerhardt Attard; David Olmos; Eric J. Small; Marniza Saad; Elena Castro; Won Kim; Daphne Wu; Kristi Bertzos; Shiva Dibaj; Jenny Zhang; Peter Francis; Matthew R. Smith
Niraparib plus abiraterone acetate plus prednisone (NIRA plus AAP) as first-line treatment in patients with BRCA plus metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
ANNALS OF ONCOLOGY
IF65.4
2023-11-010
PRE
Saad, M.; Chi, K. N.; Sandhu, S. K.; Attard, G.; Ye, D.; Li, L.; Jung, W.; Pang, S-T.; Francis, P. S. J.; Li, S.; Dibaj, S.; Zhang, J.; Kim, W.; Lopez-Gitlitz, A.; Wu, D.; Singh, A.; De Vries, R.; Zhang, L.; Lee, J. Y.
Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
ANNALS OF ONCOLOGY
IF65.4
2023-10-015
OAAI
Chi, K. N. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S. K.; Efstathiou, E.; Roubaud, G.; Small, E. J. J.; Gomes, A. J. P. D. S.; Rathkopf, D.; Saad, M.; Gurney, H. P.; Jung, W.; Mason, G. E.; Dibaj, S.; Wu, D.; Diorio, B.; Lopez-Gitlitz, A.; Kim, W.; Olmos, D.
Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA plus AAP) in homologous recombination repair gene-altered (HRR plus ) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
ANNALS OF ONCOLOGY
IF65.4
2023-10-011
OA
Attard, G.; Sandhu, S. K.; Rathkopf, D.; Castro, E.; Saad, M.; Smith, M. R.; Small, E. J. J.; Olmos, D.; Gomes, A. J. P. D. S.; Roubaud, G.; Zurawski, B.; Efstathiou, E.; Wu, D.; Diorio, B.; Urtishak, K.; Singh, U.; Xu, Y.; Lopez-Gitlitz, A.; del Corral, A.; Chi, K. N. N.
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

尼拉帕利加醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌和同源重组修复基因改变的患者: 随机III期试验的第二次中期分析

ANNALS OF ONCOLOGY
IF65.4
2023-09-0168
OAAI
Chi, K. N.; Sandhu, S.; Smith, M. R.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Gomes, A. J. Pereira de Santana; Small, E. J.; Rathkopf, D. E.; Gurney, H.; Jung, W.; Mason, G. E.; Dibaj, S.; Wu, D.; Diorio, B.; Urtishak, K.; del Corral, A.; Francis, P.; Kim, W.; Efstathiou, E.
Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA plus AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
ANNALS OF ONCOLOGY
IF65.4
2021-09-010
OAAI
Oudard, S. M.; Bevans, K. B.; Attard, G.; Efstathiou, E.; Flaig, T. W.; Franke, F. A.; Goodman, O. B., Jr.; De Giorgi, U.; Pieczonka, C. M.; Yeruva, K.; De Porre, P.; Brookman-May, S. D.; Dibaj, S.; Wu, D.; Mundle, S. D.; McCarthy, S.; Steuber, T.; Suzuki, H.; Rathkopf, D. E.; Saad, F.

研究方向

暂未获取到该数据
D
Dana E. Rathkopf
H 指数:57论文数:497被引数:2.8万
M
Marniza Saad
H 指数:16论文数:85被引数:1,606
E
Eleni Efstathiou
H 指数:62论文数:412被引数:2.1万
E
Eric J. Small
H 指数:118论文数:1,322被引数:6.8万
S
Shahneen Sandhu
H 指数:81论文数:650被引数:3.5万
P
Prabhat Jha
H 指数:77论文数:610被引数:3.2万
G
Gerhardt Attard
H 指数:88论文数:573被引数:3.4万
D
David Olmos
H 指数:64论文数:471被引数:1.9万
S
Shiva Dibaj
H 指数:12论文数:41被引数:714
G
Guilhem Roubaud
H 指数:30论文数:325被引数:5,583